Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs SYSCO Corporation — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.63 (market cap $6.04B), while SYSCO Corporation trades at $78.38 (market cap $38.47B). The key difference: SYSCO Corporation is far larger — about 6.4× Iovance Biotherapeutics Inc. Common Stock's market cap, and SYSCO Corporation pays a 2.81% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and SYSCO Corporation for 77 Days on average.
| IOVA | SYY | |
|---|---|---|
Market Cap | $6.04B | $38.47B |
Volume | 14,805,993 | 4,808,465 |
Sector | Health | Consumer Staples |
52-Week High | $14.82 | $91.16 |
52-Week Low | $1.81 | $69.30 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $5.97B | $51.65B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SYY trades at $78.31, up 1.98% today, with a neutral technical signal and mixed earnings history. The company reported revenue growth to $81.37B in 2025, though net income margin dipped to 2.08%. Recent news highlights a $500M AI efficiency program and a $1.5B senior notes offering, signaling strategic investments. Analyst consensus is bullish with a $85.75 price target, but the stock faces headwinds from high debt levels and competitive pressures.
The outlook for SYY is cautiously optimistic, supported by steady revenue growth and a strong analyst buy rating. Key opportunities include AI-driven cost savings and market expansion, while risks involve elevated leverage and margin compression. Investors should weigh the potential for earnings acceleration against macroeconomic sensitivity in the consumer staples sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
